- • Up to 20% off your first purchase
- • Bulk quantities available
- • Citation Reward application
Sample Application
- Animal health test
- In-vitro diagnostics
- Food & Feed Safety
- Environmental Safety
- New drug discovery
Supports
- Talk to our Expert:
[email protected] -
Talk to our sales:
[email protected]
Protocol Library Download
 |
 |
Anti-TNF14/ TNFSF14/ CD258 monoclonal antibody
Anti-TNF14/ TNFSF14/ CD258 antibody for FACS & in-vivo assay
Go to TNFSF14/TNFSF14 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
MSDSProduct information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-MP1857-Ab-1/ GM-Tg-hg-MP1857-Ab-2 | Anti-Human TNFSF14 monoclonal antibody | Human |
| GM-Tg-rg-MP1857-Ab-1/ GM-Tg-rg-MP1857-Ab-2 | Anti-Rat TNFSF14 monoclonal antibody | Rat |
| GM-Tg-mg-MP1857-Ab-1/ GM-Tg-mg-MP1857-Ab-2 | Anti-Mouse TNFSF14 monoclonal antibody | Mouse |
| GM-Tg-cynog-MP1857-Ab-1/ GM-Tg-cynog-MP1857-Ab-2 | Anti-Cynomolgus/ Rhesus macaque TNFSF14 monoclonal antibody | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-MP1857-Ab-1/ GM-Tg-felg-MP1857-Ab-2 | Anti-Feline TNFSF14 monoclonal antibody | Feline |
| GM-Tg-cang-MP1857-Ab-1/ GM-Tg-cang-MP1857-Ab-2 | Anti-Canine TNFSF14 monoclonal antibody | Canine |
| GM-Tg-bovg-MP1857-Ab-1/ GM-Tg-bovg-MP1857-Ab-2 | Anti-Bovine TNFSF14 monoclonal antibody | Bovine |
| GM-Tg-equg-MP1857-Ab-1/ GM-Tg-equg-MP1857-Ab-2 | Anti-Equine TNFSF14 monoclonal antibody | Equine |
Size： 1mg | 10mg | 100mg
Product Description
| Catalog No. | GM-Tg-hg-MP1857-Ab-1/ GM-Tg-hg-MP1857-Ab-2; GM-Tg-rg-MP1857-Ab-1/ GM-Tg-rg-MP1857-Ab-2; GM-Tg-mg-MP1857-Ab-1/ GM-Tg-mg-MP1857-Ab-2; GM-Tg-cynog-MP1857-Ab-1/ GM-Tg-cynog-MP1857-Ab-2; GM-Tg-felg-MP1857-Ab-1/ GM-Tg-felg-MP1857-Ab-2; GM-Tg-cang-MP1857-Ab-1/ GM-Tg-cang-MP1857-Ab-2; GM-Tg-bovg-MP1857-Ab-1/ GM-Tg-bovg-MP1857-Ab-2; GM-Tg-equg-MP1857-Ab-1/ GM-Tg-equg-MP1857-Ab-2 |
| Products Name | Anti-TNFSF14 monoclonal antibody |
| Format | mab |
| Target Name | TNFSF14 |
| Protein Sub-location | Transmembrane Protein |
| Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody, Cytokine antibody |
| Derivation (species) | Mouse |
| CH1+2+3 Isotype (Receptor identification) | IgG |
| Type of Light Chain (VD-LC) | N/A |
| Expression platform | Mammalian Expression |
| Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
| Tag | Fc |
| Products description | Pre-made anti-TNFSF14 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
| Biosimilar | GMP-Bios-ab-688 | Pre-Made Quisovalimab biosimilar, Whole mAb, Anti-TNFSF14/CD258 Antibody: Anti-HVEML/LIGHT/LTg therapeutic antibody |
| Target Antigen | Products Developing | Multi-species TNF14/ TNFSF14/ CD258 VLP (virus-like particle) (Products Developing) |
| Cytokine | GM-Tg-g-MP1857-Ag-1 | Tumor necrosis factor superfamily member 14 (TNFSF14) protein |
| ORF Viral Vector | pGMLP003477 | human TNFSF14 Lentivirus plasmid |
| ORF Viral Vector | vGMLP003477 | human TNFSF14 Lentivirus particle |
| ORF Viral Vector | pGMLPm000508 | mouse Tnfsf14 Lentivirus plasmid |
| ORF Viral Vector | vGMLPm000508 | mouse Tnfsf14 Lentivirus particle |
Target information
| Target ID | GM-MP1857 |
| Target Name | TNFSF14 |
| Gene ID | 8740,50930,301133,701451,611306,101096542,505521,100060470 |
| Gene Symbol and Synonyms | CD258,HVEM-L,HVEML,LIGHT,LTg,Ly113,TNFSF14,Tnlg1d |
| Uniprot Accession | O43557 |
| Uniprot Entry Name | TNF14_HUMAN |
| Protein Sub-location | Transmembrane Protein |
| Category | Therapeutics Target, INN Index, Cytokine Target |
| Disease | N/A |
| Gene Ensembl | ENSG00000125735 |
| Target Classification | N/A |
The target: TNFSF14, gene name: TNFSF14, also named as CD258, HVEML, LIGHT, LTg. The protein encoded by this gene is a member of the tumor necrosis factor (TNF) ligand family. This protein is a ligand for TNFRSF14, which is a member of the tumor necrosis factor receptor superfamily, and which is also known as a herpesvirus entry mediator (HVEM). This protein may function as a costimulatory factor for the activation of lymphoid cells and as a deterrent to infection by herpesvirus. This protein has been shown to stimulate the proliferation of T cells, and trigger apoptosis of various tumor cells. This protein is also reported to prevent tumor necrosis factor alpha mediated apoptosis in primary hepatocyte. Two alternatively spliced transcript variant encoding distinct isoforms have been reported. [provided by RefSeq, Jul 2008].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.
Facebook
LinkedIn
Twitter
